Business
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC SOUTH SAN FRANCISCO,
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFindings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and immuno-oncology diagnostic tests and technology to improve outcomes for cancer patients will be shared at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in person and virtually from June 3-7, in Chicago.\n\n“The findings being presented at the ASCO annual meeting expand the performance and utility data for our clinical tests, while demonstrating the role our novel immuno-oncology offerings may play in advancing new frontiers in personalized medicine,” said Marc Stapley, Veracyte’s chief executive officer. “We are especially excited to present new data focused on determining which patients with metastatic non-small cell lung cancer may benefit from immune checkpoint inhibitors – an important clinical need that is not being met with current biomarker testing.”\n\nThe following abstracts will be shared as part of the 2022 ASCO Annual Meeting:\n\n\n\nTitle:\n\n\n\nEfficacy of anti-PD1/PD-L1 immunotherapy in non–small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status.\n\n\n\n\n\nPresenter:\n\n\n\nJérôme Galon, Ph.D., Veracyte, INSERM, France\n\n\n\n\n\nDate/Time:\n\n\n\nJune 6, 2022 at 1:15 p.m. CDT\n\n\n\n\n\nAbstract #:\n\n\n\n2509\n\n\n\n\n\nFormat:\n\n\n\nOral Presentation (Arie Crown Theater)\n\n\n\n\n\nSession:\n\n\n\nClinical Science Symposium Looking Everywhere for Determinants of Benefit From Immunotherapy\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\nInternational validation of the Immunoscore-biopsy (ISB) to guide selection and monitoring of patients treated with watch-and-wait (WW) strategy for rectal cancer.\n\n\n\n\n\nPresenter:\n\n\n\nFranck Pages, M.D., Ph.D., Université Paris Descartes, INSERM, France\n\n\n\n\n\nDate/Time:\n\n\n\nJune 4, 2022 at 8:00 a.m. CDT\n\n\n\n\n\nAbstract #:\n\n\n\n3517 (Poster #311)\n\n\n\n\n\nFormat:\n\n\n\nPoster Discussion\n\n\n\n\n\nSession:\n\n\n\nGastrointestinal Cancer—Colorectal and Anal\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\nAssociation of pretreatment (preTx) tumor ...